These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 23277542)

  • 1. Domain-specific c-Myc ubiquitylation controls c-Myc transcriptional and apoptotic activity.
    Zhang Q; Spears E; Boone DN; Li Z; Gregory MA; Hann SR
    Proc Natl Acad Sci U S A; 2013 Jan; 110(3):978-83. PubMed ID: 23277542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Egr1 mediates p53-independent c-Myc-induced apoptosis via a noncanonical ARF-dependent transcriptional mechanism.
    Boone DN; Qi Y; Li Z; Hann SR
    Proc Natl Acad Sci U S A; 2011 Jan; 108(2):632-7. PubMed ID: 21187408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p19ARF directly and differentially controls the functions of c-Myc independently of p53.
    Qi Y; Gregory MA; Li Z; Brousal JP; West K; Hann SR
    Nature; 2004 Oct; 431(7009):712-7. PubMed ID: 15361884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib.
    Wirth M; Stojanovic N; Christian J; Paul MC; Stauber RH; Schmid RM; Häcker G; Krämer OH; Saur D; Schneider G
    Nucleic Acids Res; 2014; 42(16):10433-47. PubMed ID: 25147211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skp2 directs Myc-mediated suppression of p27Kip1 yet has modest effects on Myc-driven lymphomagenesis.
    Old JB; Kratzat S; Hoellein A; Graf S; Nilsson JA; Nilsson L; Nakayama KI; Peschel C; Cleveland JL; Keller UB
    Mol Cancer Res; 2010 Mar; 8(3):353-62. PubMed ID: 20197382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription.
    von der Lehr N; Johansson S; Wu S; Bahram F; Castell A; Cetinkaya C; Hydbring P; Weidung I; Nakayama K; Nakayama KI; Söderberg O; Kerppola TK; Larsson LG
    Mol Cell; 2003 May; 11(5):1189-200. PubMed ID: 12769844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arf tumor suppressor disrupts the oncogenic positive feedback loop including c-Myc and DDX5.
    Tago K; Funakoshi-Tago M; Itoh H; Furukawa Y; Kikuchi J; Kato T; Suzuki K; Yanagisawa K
    Oncogene; 2015 Jan; 34(3):314-22. PubMed ID: 24469041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myc-ARF (alternate reading frame) interaction inhibits the functions of Myc.
    Datta A; Nag A; Pan W; Hay N; Gartel AL; Colamonici O; Mori Y; Raychaudhuri P
    J Biol Chem; 2004 Aug; 279(35):36698-707. PubMed ID: 15199070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence.
    Lin HK; Chen Z; Wang G; Nardella C; Lee SW; Chan CH; Yang WL; Wang J; Egia A; Nakayama KI; Cordon-Cardo C; Teruya-Feldstein J; Pandolfi PP
    Nature; 2010 Mar; 464(7287):374-9. PubMed ID: 20237562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.
    Eischen CM; Roussel MF; Korsmeyer SJ; Cleveland JL
    Mol Cell Biol; 2001 Nov; 21(22):7653-62. PubMed ID: 11604501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kaposi sarcoma-associated herpesvirus vIRF-3 protein binds to F-box of Skp2 protein and acts as a regulator of c-Myc protein function and stability.
    Baresova P; Pitha PM; Lubyova B
    J Biol Chem; 2012 May; 287(20):16199-208. PubMed ID: 22453922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ARF tumor suppressor: keeping Myc on a leash.
    Gregory MA; Qi Y; Hann SR
    Cell Cycle; 2005 Feb; 4(2):249-52. PubMed ID: 15655352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The G1 phase E3 ubiquitin ligase TRUSS that gets deregulated in human cancers is a novel substrate of the S-phase E3 ubiquitin ligase Skp2.
    Jamal A; Swarnalatha M; Sultana S; Joshi P; Panda SK; Kumar V
    Cell Cycle; 2015; 14(16):2688-700. PubMed ID: 26038816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1.
    Eischen CM; Packham G; Nip J; Fee BE; Hiebert SW; Zambetti GP; Cleveland JL
    Oncogene; 2001 Oct; 20(48):6983-93. PubMed ID: 11704823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.
    Meng X; Carlson NR; Dong J; Zhang Y
    Oncogene; 2015 Nov; 34(46):5709-17. PubMed ID: 25823025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The non-enzymatic RAS effector RASSF7 inhibits oncogenic c-Myc function.
    Kumaraswamy A; Mamidi A; Desai P; Sivagnanam A; Perumalsamy LR; Ramakrishnan C; Gromiha M; Rajalingam K; Mahalingam S
    J Biol Chem; 2018 Oct; 293(40):15691-15705. PubMed ID: 30139745
    [No Abstract]   [Full Text] [Related]  

  • 17. The Myc-nucleophosmin-ARF network: a complex web unveiled.
    Li Z; Hann SR
    Cell Cycle; 2009 Sep; 8(17):2703-7. PubMed ID: 19652540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implication of the ubiquitin/proteasome system in Myc-regulated transcription.
    von der Lehr N; Johansson S; Larsson LG
    Cell Cycle; 2003; 2(5):403-7. PubMed ID: 12963825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.
    Hemann MT; Bric A; Teruya-Feldstein J; Herbst A; Nilsson JA; Cordon-Cardo C; Cleveland JL; Tansey WP; Lowe SW
    Nature; 2005 Aug; 436(7052):807-11. PubMed ID: 16094360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skp2 regulates Myc protein stability and activity.
    Kim SY; Herbst A; Tworkowski KA; Salghetti SE; Tansey WP
    Mol Cell; 2003 May; 11(5):1177-88. PubMed ID: 12769843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.